www.fdanews.com/articles/73050-ziopharm-completes-18-million-financing
ZIOPHARM Completes $18 Million Financing
June 6, 2005
ZIOPHARM announced that it had completed its Series A Convertible Preferred Stock offering. Paramount BioCapital served as the lead placement agent and gross proceeds were approximately $18.1 million. The net proceeds from the offering will be used for research and development, licensing fees and expenses, and for working capital and general corporate purposes. ZIOPHARM is a development stage biopharmaceutical company that seeks to acquire, develop and commercialize, on its own or with other commercial partners, products for the treatment of important unmet medical needs in cancer.
Yahoo News (http://biz.yahoo.com/bw/050606/65073.html?.v=1)